Skip to content

Study · Non-randomized trial · n = 4 · 2016

4 results

Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels.

Narayanaswamy S, Jayasena CN, Ng N, Ratnasabapathy R, Prague JK, Papadopoulou D, Abbara A, Comninos AN, Bassett P, Bloom SR, Veldhuis JD, Dhillo WS

Clinical endocrinology17 Dec 2015Cited by 32 (Europe PMC)

PMID26572695 (opens in a new tab)PMCIDPMC4914955 (opens in a new tab)DOI10.1111/cen.12977 (opens in a new tab)PepBankPUB-26572695
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Background and objectiveKisspeptin stimulates hypothalamic GnRH secretion resulting in gonadotrophin release and has potential as a future therapeutic. Chronic subcutaneous infusion of kisspeptin via a pump (similar to an insulin pump) may provide an alternative route of administration in the future. We investigated for the first time in humans, the gonadotrophin response to subcutaneous (SC) infusions of kisspeptin-54 in healthy women. Women are markedly more responsive to exogenous kisspeptin in the late follicular phase preovulation when oestradiol levels are naturally high. Therefore, we further investigated whether there was a correlation between baseline oestradiol levels and LH response to kisspeptin.Design and patientsA prospective, single-blinded placebo-controlled study. Healthy women (n = 4) received an 8-h SC infusion of kisspeptin-54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles. Gonadotrophins and oestradiol were measured every 10 min during the infusions.ResultsSC infusion of kisspeptin-54 increased LH and FSH. The LH response to SC infusion of kisspeptin-54 (0·3 and 1·0 nmol/kg/h) positively correlated with baseline oestradiol levels (P < 0·001). Further statistical analyses showed that in the 1·0 nmol/kg/h group, a 100pmol/l rise in baseline oestradiol was associated with a 1·0 IU/l increase in LH.ConclusionsKisspeptin administered via a SC infusion could be a viable future therapeutic route of administration for patients with infertility. Baseline oestradiol levels may be an important determinant of the gonadotrophin response to kisspeptin treatment in women and should be taken into consideration when evaluating gonadotrophin response.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy women, subcutaneous infusion of kisspeptin‑54 increased LH.

    In plain wordsIn healthy women, kisspeptin‑54 given under the skin by infusion raised luteinising hormone.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseLH increase with subcutaneous kisspeptin-54 infusion
    Study

    n = 4

    Comparator
    Saline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0·1, 0·3 or 1·0 nmol/kg/h · subcutaneous infusion · 8 hAs given in this study (human).

    Source sentences

    Summary
    SC infusion of kisspeptin-54 increased LH and FSH.
    1 context sentence
    Summary · context
    Healthy women (n = 4) received an 8-h SC infusion of kisspeptin-54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy women, subcutaneous infusion of kisspeptin‑54 increased FSH.

    In plain wordsIn healthy women, kisspeptin‑54 given under the skin by infusion raised follicle-stimulating hormone.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseFSH increase with subcutaneous kisspeptin-54 infusion
    Study

    n = 4

    Comparator
    Saline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0·1, 0·3 or 1·0 nmol/kg/h · subcutaneous infusion · 8 hAs given in this study (human).

    Source sentences

    Summary
    SC infusion of kisspeptin-54 increased LH and FSH.
    1 context sentence
    Summary · context
    Healthy women (n = 4) received an 8-h SC infusion of kisspeptin-54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles.
  3. 03HumanNon-randomized trialMechanism

    In healthy women, the LH response to subcutaneous kisspeptin‑54 infusion at the two higher doses correlated positively with baseline oestradiol (P < 0·001).

    In plain wordsIn healthy women, a higher starting oestradiol level was linked to a bigger luteinising hormone response to kisspeptin‑54.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseLH response correlation with baseline oestradiol
    Study

    n = 4

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0·3 and 1·0 nmol/kg/h · subcutaneous infusion · 8 hAs given in this study (human).

    Source sentences

    Summary
    The LH response to SC infusion of kisspeptin-54 (0·3 and 1·0 nmol/kg/h) positively correlated with baseline oestradiol levels (P < 0·001).
    1 context sentence
    Summary · context
    Healthy women (n = 4) received an 8-h SC infusion of kisspeptin-54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles.
  4. 04HumanNon-randomized trialMechanism

    In healthy women at the highest dose, a 100 pmol/l rise in baseline oestradiol was associated with a 1·0 IU/l increase in LH.

    In plain wordsIn healthy women at the highest dose, a higher starting oestradiol level was linked to a bigger luteinising hormone rise.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseLH increase per rise in baseline oestradiol at the highest dose
    Study

    n = 4

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1·0 nmol/kg/h · subcutaneous infusion · 8 hAs given in this study (human).

    Source sentences

    Summary
    Further statistical analyses showed that in the 1·0 nmol/kg/h group, a 100pmol/l rise in baseline oestradiol was associated with a 1·0 IU/l increase in LH.
    1 context sentence
    Summary · context
    Healthy women (n = 4) received an 8-h SC infusion of kisspeptin-54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.